Randomized phase II trial of first-line gefitinib, gemcitabine or docetaxel in performance status (PS) 2 or 3 non-small cell lung cancer (NSCLC) patients (IFCT-0301): elderly patients analysis

Authors :: Denis Moro-Sibilot
Fabrice Barlesi
K. Chouahnia
Pierre-Jean Souquet
Bernard Lebeau
Franck Morin
Thierry Urban
Virginie Westeel
G. Des Guetz
Valérie Gounant
Fabien Vaylet
L. Baudrin
Gislaine Fraboulet
Denis Braun
Didier Debieuvre
J.-F. Morere
Source :: Critical Reviews in Oncology/Hematology. 68:S47
Publication Year :: 2008
Publisher :: Elsevier BV, 2008.

Subjects :: Oncology
medicine.medical_specialty
Performance status
business.industry
First line
non-small cell lung cancer (NSCLC)
Hematology
medicine.disease
Gemcitabine
Gefitinib
Docetaxel
Internal medicine
medicine
business
medicine.drug

Full Text Access

Tools